Adalta Ltd. · ASX:1AD
Adalta — BIO Digital 2020
19 slides from Adalta's conference presentation, Jun 5, 2020
Slide 1: AdAlta to present at BIO Digital 2020
5 June 2020 ASX Announcement For personal use only ADALTA TO PRESENT AT BIO DIGITAL 2020 MELBOURNE Australia, 5 June 2020: AdAlta Limited (ASX:1AD), the biotechnology company developing novel therapeutic products against challenging drug targets using its i-body platform will present at BIO Digital
Slide 2: About AdAlta and contacts
partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats. Further information can be found at: http://adalta.com.au For personal use only For more information, please contact: Investors Media
Slide 3: i-bodies: drugging difficult targets for next generation protein therapeutics
For personal use only i-bodies: drugging difficult targets for next generation protein therapeutics BIO2020, 8-12 June 2020 AdAlta Limited (ASX:1AD) Tim Oldham, CEO and Managing Director [email protected]
Slide 4: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 5: Next generation protein therapeutics
For personal use only “Next generation protein therapeutics” “Drugging difficult targets” AdAlta Limited (ASX:1AD) is using its unique i-body platform to discover and develop next generation protein therapeutics acting on your most challenging drug targets 3
Slide 6: AdAlta's defining features
AdAlta’s defining features For personal use only Multi-dimensional growth strategy Additional: AD-214 indications; pipeline products; discovery and development partnerships Discovery collaboration with GE Healthcare Partner target + AdAlta i-body discovery engine = targeting challenge solved Validat
Slide 7: Opportunities for our partners
Opportunities for our partners For personal use only Product partners • License to AD-214 (and future products) Platform partners • Co-develop solutions to drug targeting challenges Financial partners • Buy platform potential at single product price 5
Slide 8: i-bodies: designed for difficult to drug targets
i-bodies: designed for “difficult to drug” targets Other Partnering For personal use only CDR3 CDR3 CDR1 Unique i-body properties CDR1 Shark • Small + long loop = unique epitopes Human Human • Novel, tunable pharmacology • Flexible half-life • Stable under pH, temperature cycling • Multiple routes o
Slide 9: Market opportunity for IPF (lung fibrosis)
Market opportunity for IPF (lung fibrosis) Idiopathic Pulmonary Fibrosis For personal use only (IPF) is an irreversible, unpredictable and incurable disease THE STATISTICS People living with IPF 300,000 People die from IPF every year 40,000 Median length of survival after IPF diagnosis 3.8 years Bur
Slide 10: AD-214: first in-class anti-fibrotic with potential in multiple indications
AD-214: first in-class anti-fibrotic with potential in multiple indications For personal use only AD-214 targets CXCR4 which is: Important in maintaining stem cells in bone marrow AD-214 is a potential first- Used by HIV-1 as a co-receptor for viral entry into cells in-class anti-fibrotic Associated
Slide 11: Recent AD-214 achievements
Recent AD-214 achievements Product development, Toxicology, pharmacokinetics Pre-clinical efficacy: mouse For personal use only GMP manufacturing and pharmacodynamics: non- bleomycin model human primate Receptor Occupancy - All animals Vehicle 6 120 10 mg/kg 30 mg/kg Statistical significance# to 21d
Slide 12: AD-214 next steps
Idiopathic 1Pneumology, Hannover Medical pulmonary School;fibrosis (IPF) is aITEM, Fraunhofer fatal disease DZL BREATH Patients showed variable degrees characterized by progressive 2Pathology, Hannover Medical respiratory failure. The School and 3Nuclear Medicine, Hannover Medical School, Hannover,
Slide 13: Diverse target capability supports multiple platform partnerships
Diverse target capability supports multiple platform partnerships For personal use only GPCRs Chemokine • Target • i-body libraries Brings • i-body performance • Platform IP specs >20 targets to which i-body • Discovery, • Pre-clinical, clinical Other Lysophos- Does binders* have pholipid validation
Slide 14: AdAlta's strategy, business model to create value
AdAlta’s strategy, business model to create value For personal use only Strategy Revenue model In-house pipeline Licence to pharma of drug candidates Major upfronts + milestones AD-214 i-body products in defined & royalties ”sweet spot” Outcome Invest to value inflection G (typically Phase I or II)
Slide 15: Growth trajectory to build value
Growth trajectory to build value C For personal use only Accelerate (from ~mid-2021) B Expand A (~mid 2020 to late 2021) Maximise catalysts from current funded base (2020) Market Cap: A$14 million Market Cap: ???? (26 May 2020) From … Via … Towards 2023 … • Single product, single indication, • Layin
Slide 16: Market benchmarks: reaching for the stars!
Market benchmarks: reaching for the stars! For personal use only Fibrosis Nov-19 acquired by Roche Jan-20 platform license by Jul-19 license by Boehringer $390m + $1b – Phase II Boehringer Ingelheim pipelines Ingelheim €45m + €1.1b Aug-15 BMS option to buy $?m + $1b milestones Phase I $150m + $1.25b
Slide 17: Diverse, experienced team
Diverse, experienced team Executive Board Scientific Advisory Board For personal use only Tim Oldham, PhD Dr Paul MacLeman Brian Richardson CEO & Managing Director Chair Drug discovery and development expert Mick Foley, PhD Chief Scientific Officer Liddy McCall Steve Felstead Director Clinical devel
Slide 18: AdAlta (ASX:1AD) summary
AdAlta (ASX:1AD) summary For personal use only i-body platform for generating multiple products against “difficult” targets – Internal pipeline focused on GPCRs implicated in fibrotic and inflammatory disease and cancer – External pipeline leveraging partner expertise to pursue wider range of target
Slide 19: Contacts for more information
For personal use only Contacts for more information: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au